Comparison of the effects of single predonine and predonine-iguratimod therapy on the old elderly onset arthritis.randomized controlled trial. - The effects of iguratimod therapy on the elderly onset arthritis.

Start Date01 Aug 2016

Sponsor / Collaborator-

100 Clinical Results associated with Prednisolone Sodium Succinate

100 Translational Medicine associated with Prednisolone Sodium Succinate

100 Patents (Medical) associated with Prednisolone Sodium Succinate

562

Literatures (Medical) associated with Prednisolone Sodium Succinate

01 Oct 2023·Skin Health and Disease

Ganciclovir-Induced Drug Reaction with Eosinophilia and Systemic Symptoms

Author: Mizawa, Megumi ; Fujita, Kuniko ; Furukawa, Fumina ; Mori, Shuichi ; Shimizu, Tadamichi ; Makino, Teruhiko ; Kitayama, Shohei ; Kagoyama, Ko

AbstractDrug reaction with eosinophilia and systemic symptoms (DRESS) is a severe cutaneous adverse reaction involving multiorgan failure, with a complex interaction of various drugs, human herpesvirus reactivation and immune abnormalities suggested as the aetiology. We herein present the case of a 70-year-old man with a one-week history of fever, facial oedema, erythematous macules and purpura on his trunk and extremities. He had anti-TIF1γ antibody-positive dermatomyositis and was treated with prednisolone sodium succinate (20 mg/day). Three weeks earlier, he was treated with ganciclovir (250 mg/day) for 7 days to treat asymptomatic cytomegalovirus viraemia. Laboratory investigations revealed eosinophilia with atypical lymphocytes and elevated liver enzyme levels. A histological examination showed interface dermatitis with necrotic keratinocytes, perivascular infiltration of lymphocytes and eosinophils in the upper dermis and erythrocyte extravasation without vasculitis. A lymphocyte transformation test (LTT) was positive for ganciclovir (stimulation index: 260%; normal: <180%). We diagnosed DRESS caused by ganciclovir on the basis of clinical findings and course (Definite; RegiSCAR score: 7). He was treated with prednisolone sodium succinate (40 mg/day) and topical clobetasol propionate (0.05%) ointment twice daily. After the initiation of treatment, the skin lesions and laboratory abnormalities gradually improved. To our knowledge, this is the first case of DRESS caused by ganciclovir. The patients in whom ganciclovir is used are often immunosuppressed and may be overlooked as the causative drug for DRESS by conventional skin tests. We considered that LTT is useful for identifying causative drugs of DRESS, especially in immunosuppressed patients, such as the present case.

01 Mar 2023·Interventional Radiology

Prophylactic Steroids for Preventing Postembolization Syndrome after Transcatheter Arterial Embolization of Renal Angiomyolipoma: A Comparative Study

Article

Author: Wada, Takeshi ; Tsuchiya, Satoshi ; Aramaki, Takeshi ; Akutsu, Akira ; Uno, Takashi ; Koizumi, Jun ; Kubota, Yoshihiro ; Saiga, Atsushi ; Yokota, Hajime

PurposePostembolization syndrome (PES) after renal arterial embolization (RAE) can reduce the patient's tolerance of the procedure and extend the length of hospital stay. We aimed to assess the efficacy of steroid administration in preventing PES in patients undergoing RAE for angiomyolipoma (AML).Material and MethodsBetween May 2004 and March 2020, 29 RAE procedures in 26 patients with AML were performed. Patient information, including age, sex, tumor size, tuberous sclerosis complex-associated/sporadic AML, hemorrhagic/nonhemorrhagic AML, embolic material, steroid use, medication type, some blood laboratory parameters, hospital stay, and PES occurrence were retrospectively obtained. The prophylactic steroid protocol used in the study was as follows: 250 mg of intravenous methylprednisolone (Solu-Medrol) 2 h before the RAE procedure, followed by 2 days of intravenous prednisolone (Predonine; 2 mg/kg/day), which was tapered by halving the dose every 2 days within the course of 2 weeks. After the discharge, intravenous prednisolone was changed to oral prednisolone (Predonine). PES was defined as the presence of fever, pain, nausea, or vomiting. Data were compared between the steroid and non-steroid groups and between PES and non-PES groups.ResultsThe PES incidence rate was 76%, and a comparison between the steroid and non-steroid groups revealed that steroid use significantly decreased the incidence of PES (P < 0.001), including fever (P < 0.001), pain (P = 0.005), and nausea (P = 0.028). The use of anti-inflammatory drugs during the hospital stay was significantly lower in the steroid group (P = 0.019). Moreover, in the steroid group, C-reactive protein level was significantly lower (P = 0.006), whereas white blood cell count was significantly higher (P = 0.004). Conversely, the median length of hospital stay was not significantly shorter in the steroid group (P = 0.292).ConclusionsThe prophylactic use of steroids before and after embolization of renal AML may be effective in preventing PES in this small retrospective study.

01 Jan 2023·European Journal of Cancer

Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancer

Article

Author: Loibl, Sibylle ; Schneeweiss, Andreas ; Heeson, Sarah ; Liu, Haiying ; Kuemmel, Sherko ; Gianni, Luca ; Tan, Antoinette R ; Swain, Sandra M ; Aguila, Christian ; Macharia, Harrison ; Yang, Ke ; Dang, Chau T ; O'Shaughnessy, Joyce ; Restuccia, Eleonora

AIMTo characterise risk of anaphylaxis/hypersensitivity with intravenous pertuzumab plus trastuzumab (PH IV), the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) or concomitant chemotherapy to support potential administration of PH FDC SC by healthcare professionals outside clinics.METHODSA cumulative search for anaphylaxis/hypersensitivity (Roche Standard Adverse Event Group Terms) was performed for all pivotal trials cited in the current EMA P IV/PH FDC SC summaries of product characteristics: MBC: NCT00567190, NCT02402712; EBC: NCT01358877, NCT00545688, NCT00976989, NCT02132949, NCT03493854 and NCT03674112. Occurrence, incidence and severity of events were analysed and a time-trend analysis (by cycle) was performed.RESULTSThis analysis includes 4772 patients who received PH IV and/or PH FDC SC. Incidence of all-grade (grade ≥3) anaphylaxis/hypersensitivity events: 3-11% (≤2%) for PH IV MBC trials; 1-13% (0-3%) for PH IV EBC trials; and 2-3% (<1%; not related to PH FDC SC) for PH FDC SC EBC trials. Discontinuations due to anaphylaxis/hypersensitivity were rare for PH IV (generally <1% except two arms of TRYPHAENA: 1% and 3%); no discontinuations of PH FDC SC have been recorded so far. Time-trend analysis showed that most events were reported during the first 6-8 cycles with concurrent chemotherapy, with a decrease in later cycles (except MetaPHER).CONCLUSIONPH IV and PH FDC SC were well tolerated, with few grade ≥3 anaphylaxis/hypersensitivity events reported with PH IV and no grade ≥3 related events with PH FDC SC. Most events occurred during chemotherapy.

100 Deals associated with Prednisolone Sodium Succinate

External Link

KEGG	Wiki	ATC	Drug Bank
D01239	Prednisolone Sodium Succinate	D07XA02 D07AA03 S02BA03 A07EA01 C05AA04 S03BA02 S01CB02 H02AB06 R01AD02 S01BA04	DB14633

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Adrenal Cortex Diseases	Japan	Shionogi Pharma Co., Ltd.	24 Dec 1960
Ankylosing Spondylitis	Japan	Shionogi Pharma Co., Ltd.	24 Dec 1960
Asthma	Japan	Shionogi Pharma Co., Ltd.	24 Dec 1960
Collagen Diseases	Japan	Shionogi Pharma Co., Ltd.	24 Dec 1960
Encephalomyelitis	Japan	Shionogi Pharma Co., Ltd.	24 Dec 1960
Granulomatosis With Polyangiitis	Japan	Shionogi Pharma Co., Ltd.	24 Dec 1960
Heart Failure	Japan	Shionogi Pharma Co., Ltd.	24 Dec 1960
Juvenile Idiopathic Arthritis	Japan	Shionogi Pharma Co., Ltd.	24 Dec 1960
Leukemia	Japan	Shionogi Pharma Co., Ltd.	24 Dec 1960
Microscopic Polyangiitis	Japan	Shionogi Pharma Co., Ltd.	24 Dec 1960
Multiple Sclerosis	Japan	Shionogi Pharma Co., Ltd.	24 Dec 1960
Myasthenia Gravis	Japan	Shionogi Pharma Co., Ltd.	24 Dec 1960
Polymyositis	Japan	Shionogi Pharma Co., Ltd.	24 Dec 1960
Pulmonary Fibrosis	Japan	Shionogi Pharma Co., Ltd.	24 Dec 1960
Rheumatic Fever	Japan	Shionogi Pharma Co., Ltd.	24 Dec 1960
Rheumatoid Arthritis	Japan	Shionogi Pharma Co., Ltd.	24 Dec 1960
Systemic Lupus Erythematosus	Japan	Shionogi Pharma Co., Ltd.	24 Dec 1960
Systemic Vasculitis	Japan	Shionogi Pharma Co., Ltd.	24 Dec 1960
Thyroid Diseases	Japan	Shionogi Pharma Co., Ltd.	24 Dec 1960
Thyroiditis, Subacute	Japan	Shionogi Pharma Co., Ltd.	24 Dec 1960

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


MP87-07 (AUA2015)	Phase 2	Castration-Resistant Prostatic Cancer	120	Intermittent Docetaxel and Prednisolone (DP)	zvrhhocyhl(sssiaxxldt) = mruonopwlf bzayymsfmn (qawtpuhojl ) View more	-	01 Apr 2015

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Prednisolone Sodium Succinate

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation